Immunotherapy receives fast track designationFebruary 22, 2017Lymphoma & Plasma Cell DisordersTransplantationHodgkin LymphomaNon-Hodgkin LymphomaAggressive Lymphomas
Proximity to oil, gas wells linked to ALLFebruary 16, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersALLNon-Hodgkin Lymphoma
Drug produces high response rates in AITLFebruary 16, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
Investigators report new risk loci for CLLFebruary 9, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Obinutuzumab approved to treat FL in CanadaFebruary 8, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
NCCN releases patient guidelines for WM/LPLFebruary 7, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
OS is worse with refractory vs relapsed PTCLFebruary 3, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
Therapy granted PIM designation for CTCLFebruary 3, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin Lymphoma
Regimens seem similarly effective in ENKTLFebruary 2, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
Group proposes new prognostic model for PTCL-NOSFebruary 1, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
Project provides insight into T-cell lymphomaFebruary 1, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
Brentuximab vedotin bests standard of care in CTCLJanuary 31, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
Combo granted orphan designation for DLBCLJanuary 27, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin Lymphoma
Study quantifies 5-year survival rates for blood cancersJanuary 25, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaAMLALLHodgkin LymphomaCML
Improving the efficacy of obinutuzumabJanuary 24, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas